Patents by Inventor Jason Xiang

Jason Xiang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20070225327
    Abstract: The present invention relates to biaryl sulfonamides and their use as, for example, metalloproteinase inhibitors.
    Type: Application
    Filed: May 31, 2007
    Publication date: September 27, 2007
    Applicant: Wyeth
    Inventors: Jason Xiang, Steve Tam, Yonghan Hu, Phaik-Eng Sum, David How, Darrin Hopper, Matthew Vera, Joshua Sabatini, Thomas Rush, Elisabeth Morris, Katy Georgiadis
  • Publication number: 20070219198
    Abstract: This invention relates to inhibiting 11?HSD1.
    Type: Application
    Filed: February 7, 2007
    Publication date: September 20, 2007
    Applicant: Wyeth
    Inventors: Jason Xiang, Eddine Saiah, Steve Tam, John Mckew, Lihren Chen, Manus Ipek, Katherine Lee, Huan-Qiu Li, Jianchang Li, Wei Li, Tarek Mansour, Vipin Suri, Richard Vargas, Yuchuan Wu, Zhao-Kui Wan, Jinbo Lee, Eva Binnun, Douglas Wilson
  • Publication number: 20070043066
    Abstract: The present invention relates to modulators of metalloproteinase activity.
    Type: Application
    Filed: July 11, 2006
    Publication date: February 22, 2007
    Applicant: Wyeth
    Inventors: Phaik-Eng Sum, David How, Joshua Sabatini, Jason Xiang, Manus Ipek, Eric Feyfant
  • Publication number: 20060025445
    Abstract: This invention relates to inhibiting 11-beta HSD1.
    Type: Application
    Filed: August 2, 2005
    Publication date: February 2, 2006
    Inventors: Jason Xiang, John McKew, Steve Tam, Manus Ipek, Vipin Suri, Tarek Mansour
  • Publication number: 20060004066
    Abstract: The present invention relates to methods of treating ADAMTS-5-associated diseases and particularly osteoarthritis comprising administering an agent capable of modulating ADMATS-5 activity to a subject afflicted with the disease. The agent is preferably a biaryl sulfonamide compound. The invention is based, in part, on the discovery that transgenic animals that do not express functional ADAMTS-5 show a reduction in the degree of osteoarthritis after the induction of osteoarthritis as compared to WT animals. Furthermore, the ADAMTS-5 transgenic animals have reduced aggrecanase activity in articular tissue as compared to WT animals. These animals are good models for ADAMTS-5-associated diseases, and for screening of drugs useful in the treatment and/or prevention of these diseases. There are no other animal models in which the deletion of the activity of a single gene is capable of abrogating the course of osteoarthritis.
    Type: Application
    Filed: November 8, 2004
    Publication date: January 5, 2006
    Applicant: Wyeth
    Inventors: Elisabeth Morris, Sonya Glasson, Jason Xiang
  • Publication number: 20050143422
    Abstract: The present invention relates to biaryl sulfonamides and their use as, for example, metalloproteinase inhibitors.
    Type: Application
    Filed: December 1, 2004
    Publication date: June 30, 2005
    Applicant: Wyeth
    Inventors: Jeremy Levin, Thomas Rush, Frank Lovering, Yonghan Hu, Jianchang Li, Wei Li, Jun Wu, Rajeev Hotchandani, Jason Xiang, Xuemei Du, Derek Cole, Steve Tam
  • Publication number: 20050130973
    Abstract: The present invention relates to biaryl sulfonamides and their use as, for example, metalloproteinase inhibitors.
    Type: Application
    Filed: December 1, 2004
    Publication date: June 16, 2005
    Applicant: Wyeth
    Inventors: Jason Xiang, Steve Tam, Yonghan Hu, Phaik-Eng Sum, David How, Darrin Hopper, Matthew Vera, Joshua Sabatini, Thomas Rush, Elisabeth Morris, Katy Georgiadis